Pulse Biosciences ROA 2016-2024 | PLSE
Pulse Biosciences ROA - Return on Assets Historical Data | |||
---|---|---|---|
Date | TTM Net Income | Total Assets | Return on Assets |
2024-12-31 | $-0.05B | $0.13B | -67.52% |
2024-09-30 | $-0.05B | $0.09B | -76.35% |
2024-06-30 | $-0.04B | $0.04B | -82.24% |
2024-03-31 | $-0.04B | $0.05B | -69.08% |
2023-12-31 | $-0.04B | $0.06B | -63.70% |
2023-09-30 | $-0.04B | $0.07B | -55.36% |
2023-06-30 | $-0.05B | $0.08B | -60.45% |
2023-03-31 | $-0.05B | $0.07B | -73.65% |
2022-12-31 | $-0.06B | $0.08B | -93.93% |
2022-09-30 | $-0.06B | $0.09B | -114.80% |
2022-06-30 | $-0.06B | $0.04B | -118.81% |
2022-03-31 | $-0.06B | $0.04B | -101.24% |
2021-12-31 | $-0.06B | $0.05B | -89.36% |
2021-09-30 | $-0.06B | $0.07B | -92.19% |
2021-06-30 | $-0.06B | $0.08B | -96.83% |
2021-03-31 | $-0.06B | $0.08B | -99.13% |
2020-12-31 | $-0.05B | $0.04B | -110.50% |
2020-09-30 | $-0.05B | $0.05B | -109.89% |
2020-06-30 | $-0.05B | $0.06B | -108.29% |
2020-03-31 | $-0.05B | $0.03B | -108.89% |
2019-12-31 | $-0.05B | $0.04B | -89.10% |
2019-09-30 | $-0.04B | $0.05B | -70.00% |
2019-06-30 | $-0.04B | $0.06B | -73.21% |
2019-03-31 | $-0.04B | $0.06B | -75.36% |
2018-12-31 | $-0.04B | $0.07B | -80.42% |
2018-09-30 | $-0.04B | $0.03B | -90.48% |
2018-06-30 | $-0.03B | $0.04B | -71.96% |
2018-03-31 | $-0.03B | $0.05B | -70.06% |
2017-12-31 | $-0.03B | $0.05B | -62.11% |
2017-09-30 | $-0.02B | $0.05B | -55.47% |
2017-06-30 | $-0.02B | $0.03B | -53.57% |
2017-03-31 | $-0.01B | $0.03B | -38.26% |
2016-12-31 | $-0.01B | $0.03B | -40.40% |
2016-09-30 | $-0.01B | $0.03B | -36.78% |
2016-06-30 | $-0.01B | $0.03B | -41.38% |
2016-03-31 | $-0.01B | $0.01B | -74.07% |
2015-12-31 | $0.00B | $0.01B | -85.71% |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | MED INSTRUMENTS | $1.156B | $0.001B |
Pulse Biosciences, Inc. is a medical device company. It is engaged in developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling. NPES provide effective local tumor control and to initiate an adaptive immune response. The company deploy NPES platform applications which include human oncology, dermatology, aesthetics and other minimally invasive applications. Pulse Biosciences, Inc. is based in Burlingame, California. |